Literature DB >> 34406859

Establishment of Full-Length cDNA Clones and an Efficient Oral Infection Model for Feline Coronavirus in Cats.

Gang Wang1,2, Guangli Hu1,2, Rui Liang1,2, Jiale Shi1,2, Xiuxiu Qiu1,2, Yiling Yang1,2, Zhe Jiao1,2, Yixi Chen1,2, Zhou Shen1,2, Mengxia Li1,2, Yuejun Shi1,2, Junfu Mao3, Guiqing Peng1,2,4.   

Abstract

Feline infectious peritonitis virus (FIPV) is the etiologic agent of feline infectious peritonitis (FIP) and causes fatal disease in cats of almost all ages. Currently, there are no clinically approved drugs or effective vaccines for FIP. Furthermore, the pathogenesis of FIP is still not fully understood. There is an urgent need for an effective infection model of feline infectious peritonitis induced by FIPV. Here, we constructed a field type I FIPV full-length cDNA clone, pBAC-QS, corresponding to the isolated FIPV QS. By replacing the FIPV QS spike gene with the commercially available type II FIPV 79-1146 (79-1146_CA) spike gene, we established and rescued a recombinant virus, designated rQS-79. Moreover, we constructed 79-1146_CA infectious full-length cDNA pBAC-79-1146_CA, corresponding to recombinant feline coronavirus (FCoV) 79-1146_CA (r79-1146_CA). In animal experiments with 1- to 2-year-old adult cats orally infected with the recombinant virus, rQS-79 induced typical FIP signs and 100% mortality. In contrast to cats infected with rQS-79, cats infected with 79-1146_CA did not show obvious signs. Furthermore, by rechallenging rQS-79 in surviving cats previously infected with 79-1146_CA, we found that there was no protection against rQS-79 with different titers of neutralizing antibodies. However, high titers of neutralizing antibodies may help prolong the cat survival time. Overall, we report the first reverse genetics of virulent recombinant FCoV (causing 100% mortality in adult cats) and attenuated FCoV (causing no mortality in adult cats), which will be powerful tools to study pathogenesis, antiviral drugs, and vaccines for FCoV. IMPORTANCE Tissue- or cell culture-adapted feline infectious peritonitis virus (FIPV) usually loses pathogenicity. To develop a highly virulent FIPV, we constructed a field isolate type I FIPV full-length clone with the spike gene replaced by the 79-1146 spike gene, corresponding to a virus named rQS-79, which induces high mortality in adult cats. rQS-79 represents the first described reverse genetics system for highly pathogenic FCoV. By further constructing the cell culture-adapted FCoV 79-1146_CA, we obtained infectious clones of virulent and attenuated FCoV. By in vitro and in vivo experiments, we established a model that can serve to study the pathogenic mechanisms of FIPV. Importantly, the wild-type FIPV replicase skeleton of serotype I will greatly facilitate the screening of antiviral drugs, both in vivo and in vitro.

Entities:  

Keywords:  feline infectious peritonitis virus; pathogenesis; reverse genetics

Mesh:

Substances:

Year:  2021        PMID: 34406859      PMCID: PMC8513462          DOI: 10.1128/JVI.00745-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Molecular characterization of feline infectious peritonitis virus strain DF-2 and studies of the role of ORF3abc in viral cell tropism.

Authors:  Ádám Bálint; Attila Farsang; Zoltán Zádori; Ákos Hornyák; László Dencso; Fernando Almazán; Luis Enjuanes; Sándor Belák
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

2.  Characterization of a feline infectious peritonitis virus isolate.

Authors:  J F Evermann; L Baumgartener; R L Ott; E V Davis; A J McKeirnan
Journal:  Vet Pathol       Date:  1981-03       Impact factor: 2.221

3.  Serodiagnosis for feline infectious peritonitis by immunofluorescence using infected suckling mouse brain sections.

Authors:  T Hayashi; T Yanai; M Tsurudome; H Nakayama; Y Watabe; K Fujiwara
Journal:  Nihon Juigaku Zasshi       Date:  1981-10

4.  Establishment of an antibody avidity test to differentiate vaccinated cattle from those naturally infected with Mycoplasma bovis.

Authors:  Xiaoxiao Han; Farhan Anwar Khan; Xifang Zhu; Rui Zhang; Riaz Mustafa; Changmin Hu; Yingyu Chen; Huanchun Chen; Aizhen Guo
Journal:  Vet J       Date:  2014-11-07       Impact factor: 2.688

5.  Spike protein fusion peptide and feline coronavirus virulence.

Authors:  Hui-Wen Chang; Herman F Egberink; Rebecca Halpin; David J Spiro; Peter J M Rottier
Journal:  Emerg Infect Dis       Date:  2012-07       Impact factor: 6.883

6.  Antibody-dependent enhancement of serotype II feline enteric coronavirus infection in primary feline monocytes.

Authors:  Tomomi Takano; Mamiko Nakaguchi; Tomoyoshi Doki; Tsutomu Hohdatsu
Journal:  Arch Virol       Date:  2017-07-20       Impact factor: 2.574

7.  Recombinant feline coronaviruses as vaccine candidates confer protection in SPF but not in conventional cats.

Authors:  Ádám Bálint; Attila Farsang; Levente Szeredi; Zoltán Zádori; Sándor Belák
Journal:  Vet Microbiol       Date:  2013-10-29       Impact factor: 3.293

8.  Cellular composition, coronavirus antigen expression and production of specific antibodies in lesions in feline infectious peritonitis.

Authors:  A Kipar; S Bellmann; J Kremendahl; K Köhler; M Reinacher
Journal:  Vet Immunol Immunopathol       Date:  1998-10-23       Impact factor: 2.046

9.  Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever.

Authors:  R C Weiss; F W Scott
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1981       Impact factor: 2.268

10.  Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP.

Authors:  Tsutomu Hohdatsu; Hiroshi Yamato; Tasuku Ohkawa; Miyuki Kaneko; Kenji Motokawa; Hajime Kusuhara; Takashi Kaneshima; Setsuo Arai; Hiroyuki Koyama
Journal:  Vet Microbiol       Date:  2003-12-02       Impact factor: 3.293

View more
  1 in total

1.  Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease Inhibitors.

Authors:  Zhe Jiao; Yuanyuan Yan; Yixi Chen; Gang Wang; Xiaowei Wang; Lisha Li; Mengfang Yang; Xiaoshuai Hu; Yilin Guo; Yuejun Shi; Guiqing Peng
Journal:  J Virol       Date:  2022-08-24       Impact factor: 6.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.